JPS6364403B2 - - Google Patents
Info
- Publication number
- JPS6364403B2 JPS6364403B2 JP9805180A JP9805180A JPS6364403B2 JP S6364403 B2 JPS6364403 B2 JP S6364403B2 JP 9805180 A JP9805180 A JP 9805180A JP 9805180 A JP9805180 A JP 9805180A JP S6364403 B2 JPS6364403 B2 JP S6364403B2
- Authority
- JP
- Japan
- Prior art keywords
- sharp
- strong
- trihydroxide
- medium
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000002291 germanium compounds Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 238000012643 polycondensation polymerization Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000007859 condensation product Substances 0.000 description 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- -1 phenylgermanium trihydroxide Chemical compound 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- RQTSGHAKTDICKS-UHFFFAOYSA-N C(C)N(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCC(=O)OCC)=O Chemical compound C(C)N(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCC(=O)OCC)=O RQTSGHAKTDICKS-UHFFFAOYSA-N 0.000 description 1
- JLYUCMAHYTUPMO-UHFFFAOYSA-N C(CCC)N(C1=CC=C(C=C1)[Ge](O)(O)O)C(CC(=O)OCC)=O Chemical compound C(CCC)N(C1=CC=C(C=C1)[Ge](O)(O)O)C(CC(=O)OCC)=O JLYUCMAHYTUPMO-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- NORBRJQIBBIIGS-UHFFFAOYSA-N CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CC(=O)OCC)=O Chemical compound CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CC(=O)OCC)=O NORBRJQIBBIIGS-UHFFFAOYSA-N 0.000 description 1
- UVVSOOQCNUVURC-UHFFFAOYSA-N CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCC(=O)O)=O Chemical compound CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCC(=O)O)=O UVVSOOQCNUVURC-UHFFFAOYSA-N 0.000 description 1
- WPIIWMMTAOQLEV-UHFFFAOYSA-N CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCC(=O)OCC)=O Chemical compound CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCC(=O)OCC)=O WPIIWMMTAOQLEV-UHFFFAOYSA-N 0.000 description 1
- VERAXMQFIZNFRQ-UHFFFAOYSA-N CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCCC(=O)O)=O Chemical compound CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCCC(=O)O)=O VERAXMQFIZNFRQ-UHFFFAOYSA-N 0.000 description 1
- YXYBHIIMTFIDDF-UHFFFAOYSA-N CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCCC(=O)OCC)=O Chemical compound CN(C1=CC=C(C=C1)[Ge](O)(O)O)C(CCCC(=O)OCC)=O YXYBHIIMTFIDDF-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9805180A JPS5699418A (en) | 1980-07-16 | 1980-07-16 | Remedy for immune disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9805180A JPS5699418A (en) | 1980-07-16 | 1980-07-16 | Remedy for immune disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP246180A Division JPS5699491A (en) | 1979-09-19 | 1980-01-11 | Organic germanium compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5699418A JPS5699418A (en) | 1981-08-10 |
| JPS6364403B2 true JPS6364403B2 (enrdf_load_stackoverflow) | 1988-12-12 |
Family
ID=14209413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9805180A Granted JPS5699418A (en) | 1980-07-16 | 1980-07-16 | Remedy for immune disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5699418A (enrdf_load_stackoverflow) |
-
1980
- 1980-07-16 JP JP9805180A patent/JPS5699418A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5699418A (en) | 1981-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1248533A3 (ru) | Способ получени сульфамоилзамещенных производных фенэтиламина или его сол нокислой соли | |
| EP0187844A1 (en) | Polymeric iron chelators | |
| JPH0662407B2 (ja) | 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤 | |
| GB2053924A (en) | Immunosuppressive 3-hemiesters of7-oxygenated cholesterol | |
| US3268582A (en) | Phenylalkyl-carboxylic acid amides | |
| JPH0430924B2 (enrdf_load_stackoverflow) | ||
| JPS63201187A (ja) | ４−チアゾリジンカルボン酸誘導体、その製造法および医薬品組成物 | |
| KR100979077B1 (ko) | 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물 | |
| US3192253A (en) | N-substituted methoxyphenoxy-ethylamines | |
| EP0074411B1 (en) | Ascorbic acid derivatives | |
| JPS6364403B2 (enrdf_load_stackoverflow) | ||
| JPS59167564A (ja) | スルホニウム化合物 | |
| JPH06508134A (ja) | コレステロール低下トコフェロール類似体 | |
| EP0767777B1 (en) | New salts of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with organic basic cations | |
| DE2726435C3 (de) | p-Isobutylhydratropsäureguajacolester, Verfahren zu dessen Herstellung und diesen enthaltende Arzneimittel | |
| JP2569060B2 (ja) | グルタミルシスティン誘導体、その製造法およびそれを有効成分とする組織グルタチオンレベル向上剤 | |
| US3982002A (en) | Vincamine 2-ketoglutarate and compositions containing vincamine 2-ketoglutarate | |
| EP0025965A2 (en) | Organogermanium compounds, a method for producing them and pharmaceutical compositions comprising them | |
| RU2067575C1 (ru) | 4-ацетил-5-п-иодфенил-1-карбоксиметил-3-гидрокси-2,5-дигидропиррол-2-он, проявляющий анальгетическую активность | |
| US3621058A (en) | Novel formamido-cycloalkane derivatives | |
| JPH0633242B2 (ja) | 有機ゲルマニウム化合物を有効成分とする肝炎の治療剤 | |
| FI62283B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-2'-karboxifenyl-4-klorantranilsyraderivat | |
| JPS61291554A (ja) | ０（２，６−ジクロルフエニルアミノ）フエニル酢酸のエステル類およびその製法 | |
| WO1993021198A1 (en) | Novel sialylsteroid | |
| NO152252B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme derivater av 4-(n-(substituert-benzyliden)aminometyl)cykloheksan-1-karboksylsyre |